About DongKoo Bio& Pharma
DongKoo Bio& Pharma is a publicly listed company based in Seoul (South Korea) founded in 1970. Company focused on generic medicines, OTC, stem cell extraction kits, medical apparatus, cosmetics CMO services. Its chief executive, as recorded, is Youngjun Cho. Its website dongkoo.com draws about 14 thousand monthly visits. DongKoo Bio& Pharma offers products and services including Specialist Medicines, General Medicines, Cosmetics, and Medical Devices. Its focus areas include Diversified Pharmaceuticals, Biopharma Outsourcing, CDMO and Small Molecules & Peptides. Its legal entity in India is (μ£Ό)λꡬλ°μ΄μ€μ μ½ (U99999MH1977PLC010754).
Company details
DongKoo Bio Pharma is a diversified company focused on generic medicines, OTC, stem cell extraction kits, medical apparatus, Cosmetics CMO services. The company has a strong pipeline of products in various stages of developments including clinical trials, preclinical, process validation, pilot test formulation. The company is developing medicines for dermatology, urology, circulatory system, respiratory system, neuropsychiatry system, bones, and joints. The company also offers CMO services for tablets, hard capsules, soft gelatin capsules, liquids, powder external use products. It has developed stem cell extraction kits for aesthetic surgery anti-snoring oral devices for sleep apnea. The company has products in the market such as Cenilton for prostate treatment (partnership with Cerbios-pharma), Ventux for active probiotic intestinal treatment, and Dentheth ointment for gum disease treatment. The company exports its products to various countries including Vietnam, New Zealand, Thailand, Hong Kong and Singapore.
- Headquarters Seoul, South Korea
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phoneβ’β’β’β’ β’β’β’β’
- Website dongkoo.com/kor
- Legal Name Dongkoo Bio & Pharm Co. Ltd.
- Annual Revenue$168.04 M (USD)-2.64as on Dec 31, 2025
- Net Profit$34.81 M (USD)2369.74as on Dec 31, 2025
- EBITDA$12.58 M (USD)-9.01as on Dec 31, 2025
Associated legal entities of DongKoo Bio& Pharma
DongKoo Bio& Pharma operates through , (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| , CIN U99999MH1977PLC010754 | Active | 10 Aug 1977 | Nanded, Maharashtra | View details |
Products & Services of DongKoo Bio& Pharma
DongKoo Bio& Pharma offers a comprehensive portfolio of products and services, including Specialist Medicines, General Medicines, Cosmetics, and Medical Devices.
Prescription drugs for skin and general treatments
Over-the-counter drugs for everyday health
Skin care products for personal wellness
Equipment for medical and diagnostic use
People of DongKoo Bio& Pharma
1 people are tracked at DongKoo Bio& Pharma (1 in leadership).
| Name | Role | Group |
|---|---|---|
Youngjun Cho | CEO | Leadership |
Complete people profiles for DongKoo Bio& Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of DongKoo Bio& Pharma
DongKoo Bio& Pharma is a publicly listed company on the KRX with ticker symbol 006620 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date13 Feb 2018
- Listed onKRX: 6620
- Listed entityDongKoo Bio & Pharm Co. Ltd.
- Exchange sectorHealth technology
- ISINKR7006620009
- Share price3,415.00 KRW (-1.3% on the day) · 2026-10-14
- Market capitalisation93,565,688,934.00 KRW
- Price to earnings2.8
- EPS (diluted, trailing year)1,220.80 KRW
- Dividend yield3.47%
- Volume (last session)55,576
Financials of DongKoo Bio& Pharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 242.69B KRW | 50.27B KRW | 18.17B KRW |
| 2024 | 249.27B KRW | 2.04B KRW | 19.96B KRW |
| 2023 | 215.69B KRW | 11.81B KRW | 20.64B KRW |
| 2022 | 194.99B KRW | 6.61B KRW | 22.30B KRW |
| 2021 | 155.15B KRW | 9.33B KRW | 13.19B KRW |
Balance sheet, profit and loss, cash flow and ratios of , are on its company page.
Detailed financial statements for DongKoo Bio& Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Web traffic of DongKoo Bio& Pharma
The website of DongKoo Bio& Pharma (dongkoo.com) receives about 14.1K visits a month and ranks #2,395,189 among all websites worldwide, #3,283 in Biotechnology and Pharmaceuticals.
- Monthly visits14.1K
▲ 52% vs previous month
- Unique visitors4.5K
per month
- Global rank#2,395,189
among all websites
- Category rank#3,283
Health · Biotechnology and Pharmaceuticals
- Bounce rate57%
- Pages per visit1.7
- Average visit12 sec
- DevicesDesktop 26% Β· Mobile 74%
Websites whose visitors overlap most with DongKoo Bio& Pharma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
dailypharm.com | dailypharm.com | 100% | #33,384 | β | |
| celltrionph.com | 100% | 25.7K | #311,220 | View details | |
rapportian.com | rapportian.com | 91% | #392,999 | β | |
hanmi.co.kr | hanmi.co.kr | 82% | #470,713 | β | |
medipharmhealth.co.kr | medipharmhealth.co.kr | 82% | #734,516 | β | |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
| β’β’β’β’β’β’β’β’β’β’ | β’β’β’β’β’β’.com | β’β’% | β’.β’M | #β’β’β’β’β’ | β |
All 11 similar websites and full traffic analytics for DongKoo Bio& Pharma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dongkoo Bio& Pharma
Complete news archive for DongKoo Bio Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DongKoo Bio& Pharma
DongKoo Bio& Pharma was founded in 1970.
DongKoo Bio& Pharma is headquartered in Seoul, South Korea.
Youngjun Cho is the CEO of DongKoo Bio& Pharma, as recorded in our data.
Annual revenue of DongKoo Bio& Pharma is $168.04M as on Dec 31, 2025.
DongKoo Bio Pharma is a diversified company focused on generic medicines, OTC, stem cell extraction kits, medical apparatus, Cosmetics CMO services. The company has a strong pipeline of products in various stages of developments including clinical trials, preclinical, process validation, pilot test formulation. The company is developing medicines for dermatology, urology, circulatory system, respiratory system, neuropsychiatry system, bones, and joints. The company also offers CMO services for tablets, hard capsules, soft gelatin capsules, liquids, powder external use products. It has developed stem cell extraction kits for aesthetic surgery anti-snoring oral devices for sleep apnea. The company has products in the market such as Cenilton for prostate treatment (partnership with Cerbios-pharma), Ventux for active probiotic intestinal treatment, and Dentheth ointment for gum disease treatment. The company exports its products to various countries including Vietnam, New Zealand, Thailand, Hong Kong and Singapore.
DongKoo Bio& Pharma offers Specialist Medicines, General Medicines, Cosmetics, and Medical Devices.
Yes, DongKoo Bio& Pharma is publicly traded on KRX under the ticker symbol 006620.
DongKoo Bio& Pharma operates through ,.